Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer | Zendy

Chris Twelves | Zendy; Ahmad Awada | Zendy; Javier Cortés | Zendy; Louise Yelle | Zendy; Galina Velikova | Zendy; Martin Olivo | Zendy; James Song | Zendy; Corina E. Dutcus | Zendy; Peter Kaufman | Zendy

Open Access

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer

Author(s) -

Chris Twelves,

Ahmad Awada,

Javier Cortés,

Louise Yelle,

Galina Velikova,

Martin Olivo,

James Song,

Corina E. Dutcus,

Peter Kaufman

Publication year - 2016

Publication title -

breast cancer basic and clinical research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.741

H-Index - 23

ISSN - 1178-2234

DOI - 10.4137/bcbcr.s39615

Subject(s) - eribulin , capecitabine , medicine , metastatic breast cancer , oncology , breast cancer , taxane , cancer , colorectal cancer

Our secondary analyses compared survival with eribulin versus capecitabine in various patient subgroups from a phase 3, open-label, randomized study. Eligible women aged ≥18 years with advanced/metastatic breast cancer and ≤3 prior chemotherapies (≤2 for advanced/metastatic disease), including an anthracycline and taxane, were randomized 1:1 to intravenous eribulin mesylate 1.4 mg/m(2) on days 1 and 8 or twice-daily oral capecitabine 1250 mg/m(2) on days 1-14 (21-day cycles).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research